Andersen SL (2003). Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 27: 3–18.
Bardo MT, Bevins RA (2000). Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153: 31–43.
Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17: 25–30.
Biscaia M, Fernàndez B, Higuera-Matas A, Miguèns M, Viveros M-P, Garcìa-Lecumberri C et al (2008). Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55 940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology 54: 863–873.
Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G (2001). Behavioural sensitization after repeated exposure to delta-9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 158: 259–266.
Corchero J, Garcia-Gil L, Manzanares J, Fernandez-Ruiz JJ, Fuentes JA, Ramos JA (1998). Perinatal delta-9 tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate–putamen of adult female rats. Life Sci 63: 843–850.
Ellgren M, Spano SM, Hurd YL (2007). Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32: 607–615.
Gardner EL, Vorel SR (1998). Cannabinoid transmission and reward-related events. Neurobiol Disease 5: 502–533.
Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563–583.
Howlett AC (1995). Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35: 607–634.
Hohmann AF, Herkenham H (2000). Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37: 71–80.
Hoffman AF, Oz M, Caulder T, Lupica CR (2003). Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 23: 4815–4820.
Jardinaud F, Roques BP, Noble F (2006). Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice. Behav Brain Res 173: 255–261.
Kieffer BL (1999). Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20: 19–26.
Lamarque S, Taghzouti K, Simon H (2001). Chronic treatment with delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroine. Implications for vulnerability to drug addiction. Neuropharmacology 41: 118–129.
Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F et al (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1, receptor knockout mice. Science 228: 401–404.
McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley DE et al (2008). Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 324: 664–673.
Mansour A, Fox CA, Akil H, Watson SJ (1995). Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18: 22–29.
Manzanedo C, Aguilar MA, Rodriguez-Arias M, Navarro M, Minarro J (2004). Cannabinoid agonist-induced sensitization to morphine place preference in mice. NeuroReport 15: 1373–1376.
Mason Jr DJ, Lowe J, Welch SP (1999). A diminution of delta-9-tetrahydrocannabinol modulation of dynorphin A(1–17) in conjunction with tolerance development. Eur J Pharmacol 381: 105–111.
Matsuda L, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564.
Navarro M, Carrera MRA, Fratta W, Valverde O, Cossu G, Fattore L et al (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 15: 5344–5350.
Norwood CS, Cornish JL, Mallet PE, McGregor IS (2003). Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol 28: 105–114.
Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of the three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 153: 199–215.
Pickel VM, Chan J, Kash TL, Rodriguez JJ, Mackie K (2004). Compartment-specific localization of cannabinoid 1 (CB1) and μ opioid receptors in rat nucleus accumbens. Neuroscience 127: 101–112.
Pistis M, Perra S, Pillolla G, Melis M, Muntoni A-L, Gessa GL (2004). Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 56: 86–94.
Rios C, Gomes I, Devi LA (2006). μ opioid and CB1 cannabinoid receptors interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148: 387–395.
Rodriguez JJ, Mackie K, Pickel VM (2001). Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 24: 1673–1679.
Rodriguez de Fonseca F, Ramos JA, Bonnin A, Fernandez-Ruiz JJ (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4: 135–138.
Roloff AM, Thayer SA (2009). Modulation of excitatory synaptic transmission by Δ9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate. Mol Pharmacol 75: 892–900.
Romero J, Berrendero F, Manzanares J, Pérez A, Corchero J, Fuentes JA et al (1998). Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta-9-tetrahydrocannabinol. Synapse 30: 298–308.
Rubino T, Vigano D, Massi P, Spinello M, Zagato E, Giagnoni G (2000). Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39: 1331–1336.
Schoffelmeer ANM, Hogenboom F, Wardeh G, De Vries TJ (2006). Interactions between CB1 cannabinoid and μ opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51: 773–781.
Shippenberg TS, Bals-Kubik R, Herz A (1993). of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs D-2 dopamine receptors. J Pharmacol Exp Ther 265: 53–59.
Sim-Selley LJ (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91–119.
Singh ME, McGregor IS, Mallet PE (2005). Repeated exposure to delta9-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity. Neuropharmacology 49: 1189–1200.
Singh ME, McGregor IS, Mallet PE (2006). Perinatal exposure to delta-9 tetrahydrocannabinol alters heroin-induced place conditioning and Fos-immunoreactivity. Neuropsychopharmacology 31: 58–69.
Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A (1999). Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc Natl Acad Sci USA 96: 5786–5790.
Tanda G, Goldberg SR (2003). Cannabinoids: reward, dependence, and underlying neurochemical mechanisms- a review of recent preclinical data. Psychopharmacology 169: 115–134.
Valverde O, Noble F, Beslot F, Daugé V, Fournié-Zaluski M-C, Roques BP (2001). Δ9—tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 13: 1816–1824.
Van Ree JM, Niesink RJ, Van Wolfswinkel L, Ramsey NF, Kornet MM, Van Furth WR et al (2000). Endogenous opioids and reward. Eur J Pharmacol 405: 89–101.
Vazquez V, Weiss S, Giros B, Martres M-P, Daugé V (2007). Maternal deprivation and handling modify the effect of the dopamine D3 receptor agonist, BP 897 on morphine-conditioned place preference in rats. Psychopharmacology 193: 475–486.
Vazquez V, Penit-Soria J, Durand C, Besson MJ, Giros B, Daugé V (2005). Maternal deprivation increases vulnerability to morphine dependence and disturbs the enkephalinergic system in adulthood. J Neurosci 25: 4453–4462.
Vazquez V, Giros B, Daugé V (2006). Maternal deprivation specifically enhances vulnerability for opiate dependence. Behav Pharmacol 17: 715–724.
Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I (2006). Adenosine A2a blockade prevents synergy between μ-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc Natl Acad Sci USA 103: 7877–7882.
Wolffgramm J, Heyne A (1995). From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat. Behav Brain Res 70: 77–94.